FDA Grants Fast Track Designation to PBGENE-DMD for Duchenne Muscular Dystrophy

Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, its novel gene editing therapy designed to treat Duchenne muscular dystrophy (DMD).